论文部分内容阅读
目的探讨Beclin-1和Bcl-2在前列腺腺癌中的表达及意义方法采用免疫组化PV-6000法检测76例前列腺腺癌和40例前列腺结节性增生组织中Beclin-1和Bcl-2的表达。结果在前列腺腺癌组织中,Beclin-1、Bcl-2的阳性表达率分别为47.4%、39.5%;在前列腺结节性增生组织中Beclin-1、Bcl-2的阳性表达率分别为95%、12.5%。Beclin-1、Bcl-2的表达在前列腺腺癌中与前列腺结节性增生组织中有明显差异(P均<0.01);同时两者的表达与前列腺腺癌组织的Gleason评分分级有相关性,Gleason评分越高,Beclin-1的表达越弱,而Bcl-2的表达越强(P<0.05);Beclin-1在前列腺腺癌中的阳性表达与Bcl-2的阳性表达呈负相关性(r=-0.235,P<0.05)。结论 Beclin-1和Bcl-2与前列腺腺癌的发生、发展有关,联合检测有助于临床预测患者预后。
Objective To investigate the expression and significance of Beclin-1 and Bcl-2 in prostatic adenocarcinoma.Methods Immunohistochemistry PV-6000 was used to detect the expression of Beclin-1 and Bcl-2 in 76 cases of prostatic adenocarcinoma and 40 cases of benign prostatic hyperplasia expression. Results The positive rates of Beclin-1 and Bcl-2 in prostate adenocarcinoma were 47.4% and 39.5%, respectively. The positive rates of Beclin-1 and Bcl-2 in benign prostatic hyperplasia tissues were 95% , 12.5%. The expressions of Beclin-1 and Bcl-2 were significantly different between prostatic adenocarcinoma and benign prostatic hyperplasia (all P <0.01). The expression of Beclin-1 and Bcl-2 were correlated with the Gleason score of prostatic adenocarcinoma, The higher the Gleason score, the lower the expression of Beclin-1 and the higher the expression of Bcl-2 (P <0.05). The positive expression of Beclin-1 in prostatic adenocarcinoma was negatively correlated with the positive expression of Bcl-2 r = -0.235, P <0.05). Conclusions Beclin-1 and Bcl-2 are associated with the occurrence and development of prostatic adenocarcinoma. Combined detection may be helpful to predict the prognosis of patients clinically.